Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

NCT03348059 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT03348059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03348059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Completed
Start date
October 1, 2015
Completion date
March 31, 2017
Enrollment
103 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c